NasdaqGS:BNTXBiotechs
How New Lung Cancer Trial Data At BioNTech (BNTX) Has Changed Its Investment Story
In late March 2026, BioNTech SE presented updated clinical data from its diversified lung cancer portfolio at the European Lung Cancer Congress in Copenhagen, highlighting progress across late‑stage immunomodulators and antibody‑drug conjugates in multiple lung cancer subtypes and treatment lines.
The breadth of pivotal and early‑stage trials, including novel combinations such as pumitamig with a HER3‑targeted antibody‑drug conjugate, underlines how central lung cancer programs have become...